Drug name - Olysio

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(2 years from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8148399 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Sep, 2029

(6 years from now)

CN1914224B JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitor
Jan, 2020

(2 years ago)

CN1914224A JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2020

(2 years ago)

CN102627639B JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN102627639A JANSSEN PRODS Macrocyclic Inhibitor Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN103030636B JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN103030636A JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN101228169B JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN101228169A JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2020

(2 years ago)

CN1914225A JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2021

(1 year, 8 months ago)

CN1914225B JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2021

(1 year, 8 months ago)

IN200603860P1 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

IN256631B JANSSEN PRODS Cyclopentanyl Containing Macrocyclic Hcv Ns-3 Protease Inhibitors
Jan, 2025

(2 years from now)

IN294307B JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

IN200710158P1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1713822B1 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

EP1713822A2 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

EP2322516A1 JANSSEN PRODS Intermediates For The Preparation Of Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP2322516B1 JANSSEN PRODS Intermediates For The Preparation Of Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1912999A1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1912999B1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1713823B1 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
May, 2029

(6 years from now)

EP1713823A2 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus Jul, 2026

(3 years from now)

US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus Jul, 2026

(3 years from now)

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.